Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.7K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

1.1K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.1K
Adrenal Gland Disorders01:27

Adrenal Gland Disorders

1.7K
Adrenal gland disorders manifest when the production of adrenal hormones deviates from the norm, resulting in either excessive or insufficient concentrations.
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
1.7K
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

2.0K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.0K
Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

4.8K
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
4.8K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

163
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
163

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Overview of Endocrine Dysfunction in Children with Turner Syndrome.

Turkish archives of pediatrics·2026
Same author

Donohue syndrome in an Egyptian infant: a case report.

Case reports in perinatal medicine·2025
Same author

Refractory hypothyroidism in children: an overview.

Journal of pediatric endocrinology & metabolism : JPEM·2024
Same author

Gynecomastia in adolescent males: current understanding of its etiology, pathophysiology, diagnosis, and treatment.

Annals of pediatric endocrinology & metabolism·2024
Same author

Idiopathic ketotic hypoglycemia in children: an update.

Annals of pediatric endocrinology & metabolism·2024
Same author

Endothelial dysfunction in children with newly diagnosed Graves' disease.

European journal of pediatrics·2023

Related Experiment Video

Updated: Jul 31, 2025

Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma
09:06

Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma

Published on: November 11, 2021

2.6K

Graves' Disease in Children: An Update.

Kotb Abbass Metwalley1, Hekma Saad Farghaly1

  • 1Department of Pediatrics, Faculty of Medicine, Assiut University, Assiut, Egypt.

Clinical Medicine Insights. Endocrinology and Diabetes
|May 8, 2023
PubMed
Summary

Graves' disease in children, a common cause of hyperthyroidism, is diagnosed by thyroid receptor antibodies (TRAb). Current recommendations favor long-term anti-thyroid drugs (ATDs) as the primary treatment.

Keywords:
Graves’ diseaseHashimoto’s thyroiditiscarbimazolehyperthyroidismthyroid receptor antibodiesthyroid-stimulating hormone

More Related Videos

Co-culture of Glutamatergic Neurons and Pediatric High-Grade Glioma Cells Into Microfluidic Devices to Assess Electrical Interactions
07:39

Co-culture of Glutamatergic Neurons and Pediatric High-Grade Glioma Cells Into Microfluidic Devices to Assess Electrical Interactions

Published on: November 17, 2021

3.6K
Author Spotlight: A Single-Entry Point Endoscopic Intraventricular Approach for Third Ventriculostomy and Pineal Biopsy
03:13

Author Spotlight: A Single-Entry Point Endoscopic Intraventricular Approach for Third Ventriculostomy and Pineal Biopsy

Published on: June 28, 2024

730

Related Experiment Videos

Last Updated: Jul 31, 2025

Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma
09:06

Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma

Published on: November 11, 2021

2.6K
Co-culture of Glutamatergic Neurons and Pediatric High-Grade Glioma Cells Into Microfluidic Devices to Assess Electrical Interactions
07:39

Co-culture of Glutamatergic Neurons and Pediatric High-Grade Glioma Cells Into Microfluidic Devices to Assess Electrical Interactions

Published on: November 17, 2021

3.6K
Author Spotlight: A Single-Entry Point Endoscopic Intraventricular Approach for Third Ventriculostomy and Pineal Biopsy
03:13

Author Spotlight: A Single-Entry Point Endoscopic Intraventricular Approach for Third Ventriculostomy and Pineal Biopsy

Published on: June 28, 2024

730

Area of Science:

  • Pediatric Endocrinology
  • Immunology

Background:

  • Graves' disease (GD) is the leading cause of hyperthyroidism in pediatric populations.
  • Key clinical signs include goiter, suppressed TSH, and elevated FT4/FT3 levels.
  • Thyroid receptor antibodies (TRAb) are crucial for specific immunological diagnosis.

Purpose of the Study:

  • To outline the diagnostic markers and treatment modalities for pediatric Graves' disease.
  • To review current management recommendations and emerging therapies.

Main Methods:

  • Review of biochemical profiles and diagnostic criteria for pediatric GD.
  • Analysis of established treatment options: anti-thyroid drugs (ATDs), radioiodine, and thyroidectomy.
  • Evaluation of novel agents like Rituximab and Teprotumumab in the context of pediatric GD.

Main Results:

  • Diagnosis relies on clinical presentation, biochemical assays (TSH, FT4, FT3), and TRAb presence.
  • First-line management typically involves a prolonged course of ATDs (3-5+ years).
  • Efficacy and safety data for newer drugs (Rituximab, Teprotumumab) in pediatric GD are currently limited.

Conclusions:

  • Pediatric Graves' disease requires careful management considering various treatment risks and benefits.
  • Extended ATD therapy is the recommended initial approach.
  • Further research is needed to establish the role of novel therapies in children with GD.